Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics, Inc. (AQST) director John Cochran acquired 62,229 common shares on October 21, 2026. He reported direct holdings of 161,715 shares after the transaction. No Rule 10b5-1 plan is reported.
Aquestive Therapeutics, Inc. (AQST) amended and restated its bylaws, effective October 15, 2026, revising requirements for stockholder nominations to the Board. The changes eliminate a requirement to provide information about certain relationships between the nominating stockholder or a Stockholder Associated Person and people acting in concert with the proposed nominee, the nominee’s immediate family, and the nominee’s affiliates and associates. The bylaws also revise the definition of “Stockholder Associated Person” to exclude persons acting in concert with nominating stockholders or beneficial owners on whose behalf nominations or proposals are brought. Technical, conforming and non-substantive changes were also made.
Aquestive Therapeutics, Inc. (AQST) President and CEO Daniel Barber sold 25,000 shares of common stock on October 15, 2026, under a Rule 10b5-1 plan. The reported weighted average price was $4.2240 per share, with transaction prices ranging from $4.03 to $4.68. Barber reported directly held shares of 627,317 following the sale.
Aquestive Therapeutics, Inc. reported that director Richard J. Daly held 0 shares of its common stock directly following the October 15, 2026 entry.
Aquestive Therapeutics (AQST) said the FDA accepted as complete its resubmission of the New Drug Application for Anaphylm, a dibutepinephrine sublingual film candidate for Type I allergic reactions, including anaphylaxis. The FDA classified the resubmission as a Class 2 response and assigned a PDUFA goal date of March 16, 2027. Anaphylm remains subject to FDA review and approval.
Aquestive submitted the resubmission on September 16, 2026, after announcing positive topline results in August 2026 from human factors and pharmacokinetic studies conducted to address items raised in the FDA’s January 30, 2026 Complete Response Letter. The company said it remains on track to complete its Canadian New Drug Submission in Q4 2026.
Aquestive Therapeutics, Inc. granted Eton Pharmaceuticals exclusive U.S. commercialization rights to LIBERVANT® under a license agreement, subject to applicable regulatory approvals. Aquestive received a $10.0 million upfront fee and is entitled to up to an aggregate of $47.5 million in regulatory and commercial milestones, plus royalties at a mid-teens percentage rate on annual net sales. The first U.S. commercial-sale milestone is $10.0 million, reduced to $5.0 million if full FDA approval for ages 2–5 has not been received; other milestones include $2.5 million upon FDA approval for ages 6–11 and up to $35.0 million tied to specified annual U.S. net sales levels.
Under a separate supply agreement, Aquestive will serve as the exclusive manufacturer and supplier, subject to specified exceptions, for an initial 20-year term. LIBERVANT has tentative FDA approval for patients ages 2–5 and 12 and older; a Type 9 NDA to add ages 6–11 has a March 29, 2027 PDUFA target action date. Eton anticipates commercial availability in April 2027, subject to final FDA approval. Third-party research found 71% preferred or strongly preferred the film versus 13% for nasal spray, assuming equal efficacy; the results reflect stated preferences, not comparative clinical outcomes.
Aquestive Therapeutics, Inc. (AQST) is the subject of a Schedule 13G reporting Edward P. Bass’s deemed beneficial ownership of 9,385,561 common shares, approximately 7.5% of the outstanding class. The reported position includes 7,876,267 shares held by Thru Line L.P. and 1,509,294 shares held by Bass individually. Thru Line L.P. separately reports beneficial ownership of 7,876,267 shares, approximately 6.3%. Bass exercises sole voting and dispositive power over the partnership’s shares as sole director and president of its general partner, Thru Line GP L.L.C.
Aquestive Therapeutics, Inc. (AQST) ownership disclosures report that five MonoLine entities distributed shares to their owners. MonoLine RX II distributed 3,468,747 shares, MonoLine RX III 2,657,943 shares, MonoLine RX 1,688,639 shares and MonoSol RX Genpar 47,051 shares between October 2 and October 7, 2026; MonoLine Partners distributed 1,948,578 shares on October 2, 2026. Each entity is listed with zero beneficial ownership.
Douglas K. Bratton is reported as beneficial owner of 691,873 shares, approximately 0.6% of the outstanding shares. This amount includes 54,050 shares he currently has the right to acquire under vested director stock options. The report lists his sole voting and dispositive power over 637,823 shares.
Aquestive Therapeutics, Inc. (AQST) announced that Richard J. Daly was elected to its board effective October 14, 2026. He will serve as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders. The board’s number of directorships will increase from seven to eight effective October 14, with seven of the eight directors independent following his election.
Daly will receive an initial award of 57,000 stock options under the company’s 2018 Equity Incentive Plan. The options will be granted effective as of the second full trading day following the company’s next public release of quarterly or annual earnings. Their exercise price will equal the common stock’s closing market price on the Grant Date, and they will vest in annual one-third increments beginning on its first anniversary.
Aquestive Therapeutics, Inc. furnished a September 23, 2026 corporate presentation outlining its pipeline, commercialization plans and financing resources. The company says it resubmitted Anaphylm’s New Drug Application to the FDA on September 17, 2026, after receiving a Complete Response Letter dated January 30, 2026. The FDA will classify the resubmission and set the review timeline after its initial review; Aquestive intends to request expedited review, but says there is no assurance it will be granted.
Anaphylm remains investigational and is not FDA-approved. Aquestive reported $98.5 million in cash and cash equivalents as of June 30, 2026, and lists access to $75 million under a strategic funding agreement with RTW Investments and an additional $20 million under a debt facility from Oaktree Capital Management, each conditional on FDA approval of Anaphylm. The company plans to file in Canada before the end of 2026 and in the European Union in Q1 2027. AQST-108 topical gel is being pursued for atopic dermatitis as a potential initial indication; the candidate remains investigational, and safety and efficacy have not been established.